Navigation Links
Boston Scientific Exceeds Third Quarter EPS Guidance, Repurchases 30 Million Shares
Date:10/20/2011

xpected net sales, GAAP earnings and adjusted earnings for the fourth quarter and full year 2011, including expected impacts of acquisitions and the Neurovascular divestiture; our financial performance; and our POWER strategy.
If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.
These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.
As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Risks and uncertainties that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions and the market acceptance of those products; the market for our products, including the U.S. CRM market;  expected pricing environment; expected procedural volumes; clinical trial results; demographic trends; intellectual property rights; litigation; financial market conditions; the effect of our restructuring initiatives; integration of acquired companies; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Boston Scientific Completes Enrollment in Benign Stricture Study of WallFlex® Biliary RX Stent
2. Boston Scientific Launches Promus Element™ Stent System In China
3. Boston Scientific Welcomes Introduction of Medical Device Regulatory Improvement Act in U.S. Senate
4. Boston Scientific To Webcast Conference Call Discussing Third Quarter 2011 Financial Results
5. COPAN WASP® Lands at Prestigious Boston Medical Center
6. Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial
7. Boston Scientific Announces Favorable Appellate Court Ruling Affirming Non-Infringement of Johnson & Johnson Patent
8. Bluestar Silicones to Present Antimicrobial Silicones at Medical Silicones Conference in Boston
9. Clinical Data Demonstrates Long-Term Safety of Boston Scientifics Alair[TM]Bronchial Thermoplasty System
10. Boston Scientific Launches Coyote™ Balloon Catheter
11. Boston Scientific Sponsors New Patient Portal Dedicated to Pelvic Floor Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 Apama Medical, a privately ... of next-generation atrial fibrillation technologies, today announced the ... US Patent and Trademark Office (USPTO), titled "Low ... assemblies for use on expandable structures such as ... procedures. "We are grateful to the ...
(Date:6/18/2013)... Calif. , June 18, 2013  Isis Pharmaceuticals, Inc. ... today announced that management will present a general corporate update ... Open House on Tuesday, June 25 at 2:10 p.m. Pacific ... The agenda for the meeting is as follows: 2:00 p.m. ... of record as of April 26, 2013) 2:10 p.m. – ...
(Date:6/17/2013)... , June 17, 2013 Velplex, LLC announced ... a technology platform that connects buyers and sellers of ... an industry leader. Why? It,s because ... are intimately familiar with the dental industry. They have ... and have diligently worked to negotiate some of the ...
Breaking Medicine Technology:Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2TopProdeals.com Rises to Top as Discount Dental Supply Leader 2
(Date:6/18/2013)... Vienna, VA (PRWEB) June 18, 2013 As ... the increase in need for surgical equipment during childbirth comes ... the child from within the mother when she is unable ... difficult deliveries, they are associated with higher rates of complication ... addition to being harmful to the mother and child, forceps ...
(Date:6/18/2013)... The Drug Delivery Partnering Terms and ... the drug delivery partnering deals and agreements entered into ... report provides a detailed understanding and analysis of how ... majority of deals are discovery or development stage whereby ... to license the license drug delivery technology. These deals ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Parker ... protecting the rights of victims injured by defective medical ... review of Medtronic’s Infuse bone graft products are now ... a medical journal, the two studies serve up two ... effectiveness” when comparing Infuse and the traditional bone graft; ...
(Date:6/18/2013)... ENT and Allergy Associates, LLP (ENTA) does not ... , New York/New Jersey’s premier ear, nose, throat, ... offering superior healthcare to children and adults in hundreds ... York area-only considers adding to its current footprint when ... the right communities to serve, the right locations from ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 Biomet ... continue to move forward in a multidistrict litigation in ... LLP reports. According to court records, the litigation’s ... at which time the Court also convened a motions ... issues pertinent to the Biomet hip replacement litigation. ...
Breaking Medicine News(10 mins):Health News:Forceps Births Double, Obesity is Major Reason in Births Complications 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 2Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 3Health News:New Drug Delivery Partnering Terms and Agreements Market Study Report Available at MarketResearchReports.Biz 4Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 2Health News:Yale Releases the Findings of the Medtronic-Commissioned Infuse Bone Graft Study; Parker Waichman LLP Comments 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 2Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 3Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 4Health News:ENT and Allergy Associates Merges with Hudson Valley ENT, Adds Five Superb Physicians, Expands Overall County Presence 5Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 2Health News:Biomet Hip Lawsuit News: Bernstein Liebhard LLP Reports on Latest Status Conference in Federal Biomet Hip Replacement Litigation 3
... between micronutrient supplementation and reduced risk of recurrence during ... June 1 issue of The Journal of Infectious Diseases, ... tuberculosis therapy, once common before the advent of anti-TB ... therapy in most low-income countries even though poor nutrition ...
... Johnson &,Johnson will participate in the Morgan Stanley ... The Ritz-Carlton in Key Biscayne,Florida. Dominic Caruso, Vice ... Company in a session scheduled at 2:20 p.m.,(Eastern ... investors and other interested parties,by accessing the Johnson ...
... that are helping doctors diagnose and treat lung ... Lung Cancer Conference jointly organized by the European ... Association for the Study of Lung Cancer (IASLC) ... No. 81O; Friday 25th April, 16:30), Israeli researchers ...
... autism are increasingly turning to sensory integration treatment ... and theyre seeing good results. In 2007, 71 ... treatment used sensory integration methods, and 91 percent ... from Temple University researchers, presented this month at ...
... (NYSE: HRC ) fiscal 2008 second quarter earnings ... invited to view its webcast the,following morning on Wednesday, ... Release: Hill-Rom Holdings, Inc.,s Fiscal 2008 Second Quarter,Earnings Release ... released to,the public after the NYSE close on Tuesday, ...
... in OTC Private Label Market, PRINCETON, N.J., ... owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced,today ... U.S. Food and Drug,Administration to manufacture and market ... Oral Solution,(Hives-Relief), 1 mg/mL (OTC). The Office of ...
Cached Medicine News:Health News:Study shows common vitamin and other micronutrient supplements reduce risks of TB recurrence 2Health News:New genetic techniques to combat lung cancer 2Health News:Autistic mannerisms reduced by sensory treatment 2Health News:Autistic mannerisms reduced by sensory treatment 3Health News:Hill-Rom Holdings, Inc. Invites You to Join Its Fiscal 2008 Second Quarter Earnings Webcast 2Health News:Ranbaxy Receives Final Approval to Manufacture and Market Cetirizine Hydrochloride Oral Solution 2
Inquire...
Inquire...
Inquire...
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: